Sanofi: Tolebrutinib Accepted For Priority Review In U.S. For Patients With Multiple Sclerosis
ReutersMar 25, 2025 6:02 AM
March 25 (Reuters) - Sanofi SA SASY.PA:
PRESS RELEASE: TOLEBRUTINIB REGULATORY SUBMISSION ACCEPTED FOR PRIORITY REVIEW IN THE US FOR PATIENTS WITH MULTIPLE SCLEROSIS
TOLEBRUTINIB SUBMISSION ACCEPTED FOR PRIORITY REVIEW IN US FOR MS
FDA TARGET ACTION DATE FOR TOLEBRUTINIB DECISION IS SEPT 28, 2025
PERSEUS PHASE 3 STUDY RESULTS EXPECTED IN H2 2025
TOLEBRUTINIB SAFETY AND EFFICACY NOT YET EVALUATED BY REGULATORS
TOLEBRUTINIB REGULATORY SUBMISSION UNDER REVIEW IN EU
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
SpaceX IPO with Dual-Class Shares: Will Musk Secure the 25% Voting Control Denied by Tesla?
TradingKey - SpaceX is preparing for an IPO this year. According to foreign media reports, SpaceX is considering a dual-class share structure for its IPO, which would grant specific shareholders extra voting rights. In other words, Elon Musk could maintain absolute control over the company even if hTradingKey
10 hours ago
Silver Plunges 10%, Gold Tests $4,900: Is the Bull Market Over Ahead of CPI?
TradingKey - Ahead of the release of the U.S. January CPI report, financial markets experienced a sudden broad sell-off on Thursday. Alongside a sharp decline in U.S. equities, prices for commodities such as gold (XAUUSD) also plummeted. Gold dropped nearly $200 within a 30-minute window, a declineTradingKey
Fri, Feb 13
Bitcoin Price Prediction 2029-2035: Institutional Accumulation and the U.S. Treasury’s Strategic Reserve Pivot
Explore the 2026 Bitcoin landscape: From the U.S. Strategic Reserve and Michael Saylor’s $75B war chest to Cathie Wood’s 2030 forecast. Is BTC the new Digital Gold?TradingKey
Fri, Feb 13
Is SaaS Dead? The Truth Behind the Software Meltdown, the Missing Floor, and the Peak That’s Not Coming Back
TradingKey - A trillion dollars just vanished from software stocks—this piece breaks down who AI is really killing, who quietly benefits, and why cheap SaaS may be the biggest value trap of this cycle.TradingKey
Thu, Feb 12
